Monday, October 28, 2019 8:08:42 AM
Alert
DermTech (NASDAQ:DMTK)
Intraday Stock Chart
Today : Monday 28 October 2019
Click Here for more DermTech Charts.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay. This PLA code was published online with an effective date of July 1, 2019 and is included in the CPT 2020 publication. Medicare rate setting for this proprietary laboratory assay code is currently in process and is expected to be finalized effective for dates of service on or after January 1, 2020.
Burkhard Jansen, M.D., DermTech’s Chief Medical Officer commented, “The receipt of this CPT code is another step toward broadening our contracting and reimbursement success for the Pigmented Lesion Assay.”
DermTech’s Pigmented Lesion Assay uses RT-PCR to measure the gene expression of two genes, LINC00516 (long-intergenic non-coding RNA 00516) and PRAME (preferentially expressed antigen in melanoma) and identifies the malignant changes of melanoma on the genomic level.
About DermTech:
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the pricing and reimbursement of DermTech’s Pigmented Lesion Assay. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the company; (2) the inability to maintain the listing of the company’s securities on Nasdaq; (3) the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition, the ability of the company to grow and manage growth profitably and retain its key employees; (4) costs related to or resulting from the business combination; (5) changes in applicable laws or regulations; (6) the demand for the company’s services together with the possibility that the company may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties included in (x) the “Risk Factors” sections of the Registration Statement on Form S-4 filed with the SEC by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005279/en/
Sarah Dion
VP Marketing
sdion@dermtech.com
(858) 450-4222
-------------------------------------------------------------------
All posts are strictly my opinion and are not buy or sell recommendations.
Recent DMTK News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:09:04 PM
- DermTech Reports First-Quarter 2024 Financial Results • Business Wire • 05/14/2024 08:05:00 PM
- DermTech to Explore Strategic Alternatives and Implement Restructuring Plan • Business Wire • 04/18/2024 08:15:00 PM
- DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/01/2024 08:05:00 PM
- DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology • Business Wire • 03/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:01:56 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:17:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:53:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:52 PM
- DermTech Reports Fourth-Quarter 2023 Financial Results • Business Wire • 02/29/2024 09:01:00 PM
- DermTech Announces Release Date for Fourth-quarter 2023 Financial Results • Business Wire • 02/13/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:32:21 PM
- DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations • Business Wire • 01/31/2024 09:30:00 PM
- DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types • Business Wire • 01/18/2024 01:05:00 PM
- DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay • Business Wire • 01/16/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:16:22 AM
- DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) • Business Wire • 01/08/2024 01:00:00 PM
- DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/14/2023 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:02:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:02:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:01:22 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 12/04/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 11/28/2023 10:45:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM